Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
Claudin 18.2 is a novel biomarker for advanced gastric and gastroesophageal junction cancer. Patients who test positive for claudin 18.2 may be candidates for the monoclonal antibody, zolbetuximab, which directly targets this biomarker. In this episode, CANCER BUZZ speaks with Manish A. Shah, MD, FASCO, director of the Gastrointestinal Oncology Program at Weill Cornell Medicine, about how claudin 18.2 is shaping treatment decisions and some of the clinical trials pursuing more information about the potential for this biomarker. CANCER BUZZ also speaks with Sasha Watson, PharmD, outpatient medical oncology clinical pharmacist at Sylvester Comprehensive Cancer Center, about the importance of engaging the whole multidisciplinary team in biomarker testing for optimal patient outcomes.
“I often talk to my gastroenterologist and ask them to get more than 1 biopsy to make sure that we have enough tissue for now and even in the future.” - Manish A. Shah, MD, FASCO
“Instead of lumping all gastric cancers into one group, we use these biomarkers to split them out... We have more refined and tailored treatments for patients with gastroesophageal adenocarcinoma based on these biomarkers.” - Manish A. Shah, MD, FASCO
“Nurses in the infusion center are a huge help that we absolutely need, and administering this treatment would be very difficult if we didn't have scaled and experienced nurses here.” - Aleksandra (Sasha) Watson, PharmD
“What I see is just a lot of patients having hope—some new part of their cancer that we can target with a drug that we previously didn't have any options for.” - Aleksandra (Sasha) Watson, PharmD
Guests:
Manish A. Shah, MD, FASCO
Director, Gastrointestinal Oncology Program
Weill Cornell Medicine
New York, NY
Aleksandra (Sasha) Watson, PharmD
Outpatient Medical Oncology Clinical Pharmacist (GI + Sarcoma)
Sylvester Comprehensive Cancer Center
Miami, FL
Resources
